Details of the Drug

General Information of Drug (ID: DMPE9AE)

• Drug Name: L19-TNF

Indication

Disease Entry	ICD 11	Status	REF
Soft tissue sarcoma	2B57	Phase 3	[1]

• Drug Type: Fusion protein
• Cross-matching ID: TTD ID: D0RP2X

References

• [1] ClinicalTrials.gov (NCT04650984) A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma. U.S.National Institutes of Health.